Leukemia cell-rhabdovirus vaccine: Personalized immunotherapy for acute lymphoblastic leukemia

Clinical Cancer Research

Volumn 19, Issue 14, 2013, Pages 3832-3843

  Conrad, David P ^a,b,c   Tsang, Jovian ^a,b   Maclean, Meaghan ^a   Diallo, Jean Simon ^a,b   Le Boeuf, Fabrice ^a,b   Lemay, Chantal G ^a,b   Falls, Theresa J ^a   Parato, Kelley A ^a   Bell, John C ^a,b   Atkins, Harold L ^a,b,c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; LEUKEMIA CELL RHABDOVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; EX VIVO STUDY; FLOW CYTOMETRY; GAMMA RADIATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHABDOVIRUS; SPLEEN CELL; SURVIVOR; VIRUS REPLICATION;

ADOPTIVE TRANSFER; ANIMALS; BONE MARROW TRANSPLANTATION; CANCER VACCINES; CELL LINE, TUMOR; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INDIVIDUALIZED MEDICINE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, NUDE; NEOPLASM TRANSPLANTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RHABDOVIRIDAE; VERO CELLS;

EID: 84880889917     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3199     Document Type: Article

References (45)

1. Swerdlow SH, Swerdlow E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues 4th ed. Lyon, France: IARC; 2008. p. 149-78.
2. Pui C, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008;371:1030-43.
3. Robison L. Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0-20 years of age. Am Soc Hematol Educ Program Book 2011;2011:238-42.
4. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-82.
5. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007; 109:944-50.
6. Jansson J, Hsu Y-C, Kuzin II, Campbell A, Mullen CA. Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects. Leuk Res 2011;35:800-7.
7. Fielding AK. Current therapeutic strategies in adult acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2011;25:1255-79.
8. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation. Blood 2008;111:1827-33.
9. Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers MED, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica 2011;96:1113-20.
10. Verneris MR, Eapen M, Duerst R, Carpenter PA, Burke MJ, Afanasyev BV, et al. Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2010;16:1237-44.
11. Litzow M. Evolving paradigms in the therapy of Philadelphia chromosome- negative acute lymphoblastic leukemia in adults. Am Soc Hematol Educ Program Book 2009:362-70.
12. Boatsman EE, Fu CH, Song SX, Moore TB. Graft-versus-leukemia effect on infant lymphoblastic leukemia relapsed after sibling hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2010;32: 57-60.
13. Socie G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009;114:4327-36.
14. Greiner J, Ono Y, Hofmann S, Schmitt A, Mehring E, Götz M, et al. Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia. Blood 2012; 120:1282-9.
15. Wang J, Zhang W, He A, Zhao W, Cao X. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia. Oncol Rep 2011;25:519-29.
16. Köchling J, Prada J, Bahrami M, Stripecke R, Seeger K, Henze G, et al. Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine 2008;26:4669-75.
17. Dubensky TW, Reed SG. Adjuvants for cancer vaccines. Semin Immunol 2010;22:155-61.
18. Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 2006; 107:1332-41.
19. Rezvanie K, de Lavallade H. Vaccination strategies in lymphomas and leukaemias. Drugs 2011;71:1659-74.
20. Ma W, Smith T, Bogin V, Zhang Y, Ozkan C, Ozkan M, et al. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy. J Transl Med 2011;9:34.
21. Vähä-Koskela MJV, Heikkilä JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007;254:178-216.
22. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6:821-5.
23. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5:965-76.
24. Lichty BD, Power AT, Stojdl DF, Bell JC. Vesicular stomatitis virus: reinventing the bullet. Trends Mol Med 2004;10:210-6.
25. Brun J, McManus D, Lefebvre C, Hu K, Falls T, Atkins H, et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther 2010;18:1440-9.
26. Lai F, Kazdhan N, Lichty BD. Using G-deleted vesicular stomatitis virus to probe the innate anti-viral response. J Virol Methods 2008; 153:276-9.
27. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide.Mol Ther 2011;19:1008-16.
28. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007;15:1686-93.
29. Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H, et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 2004;15: 821-31.
30. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997;89:1595-601.
31. Lapteva N, Aldrich M, Rollins L, Ren W, Goltsova T, Chen S-Y, et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther 2009;17:1626-36.
32. Lehner M, Bailo M, Stachel D, Roesler W, Parolini O, Holter W. Caspase-8 dependent apoptosis induction in malignant myeloid cells by TLR stimulation in the presence of IFN-alpha. Leuk Res 2007;31: 1729-35.
33. Chiang CL-L, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011; 30:150-82.
34. Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 2010;235: 172-89.
35. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature 2012;481:278-86.
36. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, Ulland TK, et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A 2009;106: 20388-93.
37. Bridle BW, Boudreau JE, Lichty BD, Brunelliere J, Stephenson K, Koshy S, et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther 2009;17:1814-21.
38. Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 2010;18:1430-9.
39. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9.
40. Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012;72:1081-91.
41. Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, et al. Using virally expressed melanoma cDNA libraries to identify tumorassociated antigens that cure melanoma. Nat Biotechnol 2012; 30:337-43.
42. Petersen J, Purcell AW, Rossjohn J. Post-translationally modified T cell epitopes: immune recognition and immunotherapy. J Mol Med 2009; 87:1045-51.
43. Krueger KE, Srivastava S. Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteomics 2006;5:1799-810.
44. Sarkies P, Sale JE. Cellular epigenetic stability and cancer. Trends Genet 2012;28:118-27.
45. Bell JC. Oncolytic viruses: what's next? Curr Cancer Drug Targets 2007;7:127-31.